Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $17.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective boosted by investment analysts at HC Wainwright from $15.00 to $17.00 in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 41.78% from the company’s current price.

Separately, Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Down 1.4 %

Eton Pharmaceuticals stock opened at $11.99 on Monday. The company has a fifty day simple moving average of $11.51 and a 200-day simple moving average of $7.28. The firm has a market capitalization of $312.35 million, a price-to-earnings ratio of -54.50 and a beta of 1.38. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $15.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eton Pharmaceuticals in the 3rd quarter valued at about $54,000. Jane Street Group LLC purchased a new position in Eton Pharmaceuticals in the third quarter worth approximately $90,000. Renaissance Technologies LLC increased its stake in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in Eton Pharmaceuticals in the second quarter valued at $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.